A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0366-5
Full Text
Open PDFAbstract
Available in full text
Date
February 20, 2019
Authors
Publisher
Springer Science and Business Media LLC